SCHEMBL6928442

SCHEMBL6928442

OCc1cncn1CCCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 7/20 0.56
CYP11B2 P19099 7/20 0.56
COMT P21964 1/20 0.51
KDM1A O60341 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
SIGMAR1 Q99720 1/20 0.42
IDO1 P14902 1/20 0.41
CNOT7 Q9UIV1 1/20 0.40
TSHR P16473 1/20 0.40
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6599807 0.90 CYP11B1 (0.55) CYP11B1CYP11B2COMTKDM1AHDAC6
SCHEMBL8862697 0.83 CYP11B1 (0.51) CYP11B1CYP11B2COMTKDM1AHDAC6
Hydrochloric Acid SCHEMBL6924270 0.83 CYP11B1 (0.51) CYP11B1CYP11B2COMTKDM1AHDAC6
SCHEMBL6597615 0.81 CYP11B1 (0.47) CYP11B1CYP11B2IDO1TSHRLMNA
SCHEMBL3079356 0.80 CYP11B1 (0.71) CYP11B1CYP11B2IDO1POLB
SCHEMBL27482941 0.79 SMN1; SMN2 (0.47) CYP11B1CYP11B2TSHRKDM4ELMNA
SCHEMBL7247430 0.78 CYP11B1 (0.46) CYP11B1CYP11B2KDM1AHDAC6GSK3B
SCHEMBL13470151 0.78 CYP11B1 (0.49) CYP11B1CYP11B2SIGMAR1GSK3AGSK3B
SCHEMBL15613771 0.78 CYP11B1 (0.46) CYP11B1CYP11B2IDO1TSHRKDM4E
SCHEMBL21143286 0.78 SIGMAR1 (0.44) CYP11B1CYP11B2SIGMAR1IDO1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1045846-B1 IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF LG CHEMICAL LTD (KR) 2003-05-02 EP disclosed
US-6518429-B2 Anticancer agents, treating restenosis, atherosclerosis and hepatitis virus LG CHEMICAL, LTD. (KR) 2003-02-11 US disclosed
US-6472526-B1 SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE OR PHARMACEUTICALLY ACCEPTABLE SALTS OR ISOMERS THEREOF, IN PHARMACEUTICAL COMPOSITION AND INTERMEDIATES LG CHEMICAL LTD. (KR) 2002-10-29 US disclosed
US-20020137769-A1 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof LG CHEMICAL LTD. 2002-09-26 US disclosed
US-6268363-B1 ANTITUMOR LG CHEMICAL LTD. (KR) 2001-07-31 US disclosed
EP-1045846-A1 IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF LG CHEMICAL LIMITED (KR) 2000-10-25 EP disclosed
WO-1999028315-A1 IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF LG CHEMICAL LTD. (KR) 1999-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137769-A1 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof FNTA, FNTB, FDPS CYP11B1 74/4885CYP11B2 110/4885COMT 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.